<DOC>
	<DOCNO>NCT01009190</DOCNO>
	<brief_summary>Dose escalation phase 1 study PARP inhibitor PF-01367338 combination chemotherapy adult patient advance solid tumor</brief_summary>
	<brief_title>A Study Of Poly ( ADP-Ribose ) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens</brief_title>
	<detailed_description />
	<mesh_term>Rucaparib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Poly ( ADP-ribose ) Polymerase Inhibitors</mesh_term>
	<criteria>Patients histologically confirm solid tumor , Eastern Cooperative Oncology Group ( ECOG ) 0 1 Patients acceptable renal , hepatic , bone marrow function Symptomatic and/or unstable brain metastasis , Any cancer treatment within 4 week study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Dose find PARPi Chemotherapy</keyword>
</DOC>